podcast
details
.com
Share
源于细胞BioInsid的个人播客
今天3分钟我们来聊聊胰腺癌Ib/III期临床,首例患者已给药
Listen
Description
加科思JAB-23E73泛KRAS抑制剂进入胰腺癌Ib/III期临床,首例患者已给药。其覆盖90%胰腺癌KRAS突变,I期显示38.5%客观缓解率,安全性良好,或改变癌中之王治疗格局。
前往小宇宙评论区与主播互动
podcast
details
Print
Share
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
Check it
Made by
Alex Barredo
. Send your feedback to
alex@barredo.es
.